Skip to main content
SpringerLink
Log in

Fidaxomicin better value than vancomycin for C. difficile infections

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Rubio-Terres C, et al. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain. European Journal of Clinical Microbiology and Infectious Diseases : 25 Sep 2015. Available from: URL: http://doi.org/10.1007/s10096-015-2472-0

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fidaxomicin better value than vancomycin for C. difficile infections. PharmacoEcon Outcomes News 738, 16 (2015). https://doi.org/10.1007/s40274-015-2498-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2498-7

Search

Navigation